All In Biotech

Drug Trial Radar · NCT00972738

Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)

A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,214 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,214

Actual

Start

Apr 2001

Primary completion

Jul 2001

Study completion Jul 2001

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the treatment effect of montelukast versus placebo over a 2 week period in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active comparator.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • montelukast sodiumDrug

    Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.

  • Comparator: loratadineDrug

    Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.

  • Comparator: PlaceboDrug

    placebo tablet orally once daily at bedtime for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment PeriodTime frame: Baseline and over the 2-week treatment period

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.